Parabilis Medicines, Inc. Common Stock (PBLS) Stock
Fundamentals
Recent news

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
PBLS

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
PBLS

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
PBLS

Parabilis Medicines aims to raise $633 million in upsized US IPO
Parabilis Medicines aims to raise $633 million in upsized US IPO
PBLS
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 6 articles
published over the past 14 days
Latest news

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
PBLS

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
PBLS

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
PBLS

Parabilis Medicines aims to raise $633 million in upsized US IPO
Parabilis Medicines aims to raise $633 million in upsized US IPO
PBLS

Parabilis Medicines aims to raise up to $475 million in US IPO
Parabilis Medicines aims to raise up to $475 million in US IPO
PBLS

Biopharmaceutical firm Parabilis Medicines files for US IPO
Biopharmaceutical firm Parabilis Medicines files for US IPO
PBLS
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. The company leverages its proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines. To the company's knowledge, its lead product candidate, zolucatetide, is the first-ever drug to directly target the interaction between β-catenin and the T-cell factor ("TCF") family of transcription factors.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Mathai Mammen M.D., Ph.D. | CEO, President, Treasurer & Chairman | 1967 |
| Ms. Teresa L. Jurgensen J.D. | Executive VP, Secretary & General Counsel | 1978 |
| Dr. Mohammed Fawzi Benzaghou M.D. | Chief Medical Officer | 1976 |
| Mr. John McGee Ph.D. | Scientific Co-Founder, Executive Vice President & Head of Platform | — |
| Mr. Thomas Rodolpho Kotarakos | Chief Financial Officer | 1982 |
| Dr. Rohin Mhatre Ph.D. | Chief Technical Operations Officer | 1965 |
| Ms. Kristen Stants | Chief People Officer | 1973 |
| Dr. Jonathan Hurov Ph.D. | Executive Vice President of Discovery Biology | — |
| Ms. Marie Nguyen M.D. | Senior VP & Head of Clinical Development | — |
| Dr. Markus Haeberlein MSc, Ph.D. | Executive Vice President of Discovery Science | 1969 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
3 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -13.4 | +22.4 | +14.9 | -21.0 |



